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Abstract
Membrane transporters play an important role in the absorption, distribution, metabolism and excretion of drugs. The cel-
lular accumulation of many drugs is the result of the net function of efflux and influx transporters. Efflux transporters such as 
P-glycoprotein/ABCB1 have been shown to confer multidrug resistance in cancer. Although expression of uptake transport-
ers has been confirmed in cancer cells, their role in chemotherapy response has not been systematically investigated. In the 
present study we have adapted a fluorescence-based cytotoxic assay to characterize the influence of key drug-transporters 
on the toxicity of approved anticancer drugs. Co-cultures of fluorescently labeled parental and transporter-expressing cells 
(expressing ABCB1, ABCG2 or OATP2B1) were screened against 101 FDA-approved anticancer drugs, using a novel, 
automated, triple fluorescence-based cytotoxicity assay. By measuring the survival of parental and transporter-expressing 
cells in co-cultures, we identify those FDA-approved anticancer drugs, whose toxicity is influenced by ABCB1, ABCG2 or 
OATP2B1. In addition to confirming known substrates of ABCB1 and ABCG2, the fluorescence-based cytotoxicity assays 
identified anticancer agents whose toxicity was increased in OATP2B1 expressing cells. Interaction of these compounds 
with OATP2B1 was verified in dedicated transport assays using cell-impermeant fluorescent substrates. Understanding drug-
transporter interactions is needed to increase the efficacy of chemotherapeutic agents. Our results highlight the potential of the 
fluorescence-based HT screening system for identifying transporter substrates, opening the way for the design of therapeutic 
approaches based on the inhibition or even the exploitation of transporters in cancer cells.
Keywords High-throughput screen · Anticancer drugs · Cytotoxicity · ATP-binding cassette transporters · Organic Anon 
Transporting Polypeptides
Introduction
Plasma membrane proteins play important roles in regulat-
ing the cellular uptake and efflux of nutrients, xenobiotics 
and drugs. Expressed in pharmacological barriers, trans-
porters modulate the absorption, distribution, metabolism 
and excretion (ADME) of compounds (Szakács et al. 2008; 
César-Razquin et al. 2015). Drug exporters such as ABCB1 
(P-glycoprotein/Pgp), ABCG2 (Breast cancer resistance pro-
tein, BCRP) or ABCC1 (Multidrug resistance-associated 
protein 1, MRP1) belong to the ATP-binding cassette (ABC) 
superfamily, and typically mediate the transmembrane trans-
port of a wide variety of xenobiotics, drugs, lipids, sterols, and 
metabolic products by utilizing the energy of ATP hydrolysis 
(Ambudkar et al. 1999; Fletcher et al. 2010). Transporters 
mediating drug import are members of the solute carrier (SLC) 
superfamily. SLC transporters also influence drug disposition 
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and efficacy, and are sites of drug–drug interactions leading to 
toxicity (Giacomini et al. 2010; Giacomini and Huang 2013). 
One of the major SLC uptake transporters involved in ADME 
processes are members of the OATP (organic anion transport-
ing polypeptide, SLCO) family. OATPs are anion exchangers 
mediating the cellular uptake of organic compounds with a 
molecular weight of more than 300 Da in an ATP- and  Na+ 
independent manner (Roth et al. 2012). The liver-specific 
OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) are 
responsible for the hepatic detoxification of numerous drugs. 
According to recent FDA (US Food and Drug Administration) 
and EMA (European Medicines Agency) recommendations, 
these uptake transporters must be investigated for interaction 
with any novel molecular entity undergoing hepatic clear-
ance (Giacomini and Huang 2013). OATP2B1 (SLCO2B1) 
is also a multispecific transporter, mediating cellular uptake 
of a plethora of clinically applied medicines (e.g., statins, 
antihistamines, and antivirals) (Tamai and Nakanishi 2013; 
Yu et al. 2017). However, in contrast to the members of the 
OATP1B subfamily, the role of OATP2B1 in hepatic clearance 
has not yet been proven. Owing to its wider tissue expression, 
OATP2B1 may participate in drug absorption from the intes-
tine or across the blood–brain barrier (Nakanishi and Tamai 
2012; Gao et al. 2015).
In the last decade, several studies revealed that the mul-
tidrug resistance phenotype in tumors is associated with the 
overexpression of certain ABC transporters, termed multi-
drug resistance (MDR) proteins. Expressed in cancer cells, 
ABCB1, ABCG2 or ABCC1 mediate the efflux of chemo-
therapeutics, allowing the survival of multidrug-resistant 
clones despite toxic chemotherapy (Gottesman et al. 2002). 
While OATP2B1 overexpression has been demonstrated in 
various tumors (e.g., breast cancer, gliomas, bone cysts), 
its role in chemotherapy response (sensitivity) has not been 
proven (Matsumoto et al. 2015; Kovacsics et al. 2017). In 
particular, the range of OATP2B1 substrates among cur-
rently used chemotherapeutics is not known. In the present 
study, we have adapted a fluorescence-based cytotoxic 
assay to identify the influence of key drug transporters on 
the toxicity of approved anticancer drugs. By measuring 
the survival of parental and transporter-expressing cells 
in co-cultures exposed to the drugs included in the NCI 
DTP oncology drug set, we identify those FDA-approved 
anticancer drugs, whose toxicity is influenced by the drug 
transporters.
Methods
Cell lines and culture conditions
A431 and Mes-Sa cell lines, including Mes-Sa/Dx5 were 
obtained from ATCC. ABCB1 and ABCG2 were expressed 
in A431 and Mes-Sa cells using lentiviral transduction 
(Pape et al. 2015), while OATP2B1 expressing cells were 
generated as described previously (Patik et al. 2018). After 
the transduction, cell lines were tested by flow cytometry 
and were sorted based on transporter expression/function, 
and in the case of the OATP2B1-expressing cell line, on 
CD4 protein expression. Parental, SLCO2B1, ABCG2 
and ABCB1 overexpressing cell lines were transduced 
with the fluorescent protein expressing lentiviral super-
natants produced with pRRL-EF1-mCherry, -mOrange or 
-eGFP expression plasmid in a second round of transduc-
tion. Mes-Sa/Dx5-eGFP cells were repeatedly cultured in 
500 nM doxorubicin to ensure homogenous expression of 
Pgp. All cell lines were cultured at 37 °C, 5%  CO2, in 
Dulbecco’s Modified Eagle’s Medium (DMEM, SigmaAl-
drich, 52100047), supplemented with 10% FBS, 2 mM 
L-glutamine and 100 units/mL penicillin and 100 µg/mL 
streptomycin (ThermoFisher). Functional expression of 
ABCB1 and ABCG2 was regularly checked with cytotox-
icity assays using mitoxantrone in the absence or pres-
ence of tariquidar. Functional expression of OATP2B1 
in A431-2B1 was verified by the Cascade Blue uptake 
assay (Patik et al. 2018) in the presence or the absence of 
estrone-3-sulfate (Fig. S1).
Fluorescence‑based cytotoxicity assays
All experiments were performed using a robotic pipetting 
workstation (Hamilton Robotics STAR Let). Cells were 
seeded at a final cell density of 1875 cells per well in 384-
well plates in the triple co-culture (625 cells from each lines) 
and at 2500 cells per well in the A431 control and A431-2B1 
co-culture (1250 cells from both) systems. Co-cultured cells 
were incubated for 24 h at 37 °C and 5%  CO2 under humidi-
fied atmosphere prior to the addition of drugs. In the primary 
assays, compounds were added in a six-point dose response 
format with threefold dilution (the final volume was 60 µl, 
DMSO did not exceeded 1%). Six compounds (valrubicin, 
doxorubicin, daunomycin, mitoxantrone, mithramycin, 
dactinomycin) were excluded from the fluorescence-based 
screens because of their intrinsic fluorescence. 144 h after 
drug addition, fluorescence was recorded by a Perkin Elmer 
EnSpire microplate reader (GFP:  485ex/510em; mCherry: 
 585ex/610em; mOrange:  545ex/567em) by scanning the plate 
at a resolution of four points per well. Data were exported 
to a custom-made program for determining growth inhibi-
tion curves for each cell line. In confirmatory screens, com-
pounds were tested with the same method in a nine-point 
dose response format. For validation, compounds were 
confirmed in cytotoxicity assays using the PrestoBlue cell 
viability reagent (ThermoFisher), according to the manufac-
turer’s instructions.
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Data analysis
In the primary screening,  IC50 was estimated by the intercept 
of the linear regression fitted on nearest values. In the con-
firmatory screening,  IC50 values were obtained by sigmoidal 
curve fitting using the GraphPad Prism software. Differences 
of the  IC50 values between the cell lines were analyzed by 
two-sided unpaired Student t test, and results were consid-
ered statistically significant at a P value of < 0.05 (*) or 0.01 
(**). Mean  IC50 values were calculated as the average of 
3–10 replicates. The Resistance Ratio (RR) was calculated 
by dividing the  IC50 values measured against the multidrug 
resistant, transporter-expressing derivative by the cytotoxic-
ity measured in the parental cell line; the Selectivity Ratio 
(SR) is the inverse of RR. Differences were considered to be 
biologically relevant at RR > 3 or SR > 3.
Microplate‑based uptake assay
OATP-expressing A431 cells were seeded (7 × 104 cells in 
200 µl final volume/well) onto 96-well plates and cultured 
for 16–24 h at 37 °C, 5%  CO2. After reaching confluence, the 
supernatant was removed and the cells were washed three-
times with 200 µl of phosphate-buffered saline (PBS). The 
cells were preincubated in the presence of the compounds 
for 5 min at 37 °C. The amount of solvent was kept below 
0.5% throughout the study to avoid interference with the 
fluorescence of the dyes. The reaction was started with the 
addition of 50 µl Cascade Blue fluorescent dye (10 µM final 
concentration in a final volume of 100 µl) and the plate was 
incubated at 37 °C for 30 min (Patik et al. 2018). The reac-
tion was stopped by the addition of 200 µl ice-cold PBS. The 
supernatant was rapidly removed, and the cells were washed 
three-times with 200 µl ice-cold PBS. Finally, 200 µl PBS 
was added to the cells and fluorescence was measured at 
room temperature using an EnSpire fluorescent plate reader 
(Perkin Elmer) at wavelengths  401ex/419em nm.
Determination of Cascade Blue dye uptake by flow 
cytometry
A431 cells were collected after trypsinization (0.1% trypsin) 
and washed twice with uptake buffer (125  mM NaCl, 
4.8 mM KCl, 1.2 mM  CaCl2, 1.2 mM  KH2PO4, 12 mM 
 MgSO4, 25 mM MES, and 5.6 mM glucose, with the pH 
adjusted to 5.5 using 10 N NaOH/1 M HEPES). 5 × 105 cells 
were preincubated at 37 °C with or without estrone-3-sul-
fate. After preincubation, 5 µM Cascade Blue hydrazide was 
added in a final volume of 100 µl for 30 min. The reaction 
was stopped by the addition of 1 ml ice-cold PBS. The cells 
were kept on ice until flow cytometry analysis. The cellular 
fluorescence of min. 20,000 live cells was determined using 
an Attune Acoustic Focusing Cytometer (Applied Biosys-
tems, Life Technologies, Carlsbad, CA, US).
NCI DTP database and in silico screening
For in silico calculations, we focused on the NCI DTP oncol-
ogy set IV compound collection and the associated cyto-
toxicity data released in December, 2016 (https ://dtp.cance 
r.gov/). Putative substrates were identified based on correla-
tion of cytotoxicity patterns to transporter expression within 
the NCI60 panel (Szakács et al. 2004).
Materials
Chemicals
The NCI DTP oncology drug set IV, containing 101 FDA-
approved anticancer drugs, was obtained from the NCI/
NIH DTP Open Chemical Repository as 10 mM DMSO 
solutions. Compounds for the follow up experiments were 
purchased from several vendors: methotrexate (NSC-740), 
teniposide (NSC-122819) and thioplex (NSC-6396) were 
obtained from Merck Irinotecan (NSC-616348), capecit-
abine (NSC-712807), bleomycin (NSC-125066), docetaxel 
(NSC-628503) and carfilzomib (NSC-758252) were pur-
chased from SelleckChem; carboplatin (NSC-241240) was 
from Accord Healthcare; Etoposide (NSC-141540) was 
purchased from TEVA; estrone-3-sulfate and Cascade Blue 
hydrazide were from ThermoFisher Scientific.
Results
Establishment and validation of the triple 
co‑cultured cell cytotoxicity assay
We have shown earlier that the human epidermoid carci-
noma cell line A431 provides a reliable and stable model for 
the characterization of the function of MDR ABC transport-
ers ABCB1 and ABCG2 (Elkind et al. 2005; Nerada et al. 
2016). For the purpose of this study we expressed the eGFP 
fluorescent protein in parental A431 cells, and mCherry 
or mOrange in A431 cells stably expressing ABCB1/P-
glycoprotein (Pgp) or ABCG2, respectively. In addition, 
we transfected the human sarcoma cell line Mes-Sa and its 
multidrug-resistant counterparts (Mes-Sa/Dx5 and Mes-
Sa-B1) with mCherry (mCh), eGFP or mOrange (mOr), 
respectively. Transporter activity and the stable expression 
of the fluorescent tags were verified by functional assays and 
cytotoxicity experiments (Fig. S1). Correlation between the 
fluorescence intensity and cell number was maintained in the 
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triplicate co-cultures, indicating that the relative number of 
the parental and transporter-expressing cells can be reliably 
estimated by measuring the fluorescence of the individual 
cell lines in the same well (Fig. S2). Growth of the differ-
ently tagged cell lines could be selectively quantified both 
in mono- and triple co-cultures, indicating that this setup 
was amenable to a fluorescence-based cytotoxicity assay 
(Fig. 1a). The triple-fluorescence-based cytotoxicity assay 
measures the growth inhibitory effect of test compounds 
on the co-culture of differently tagged parental and trans-
porter-expressing cell lines. The assay was validated using 
etoposide, which is known to be recognized by both ABCB1 
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and ABCG2, as well as an MDR-selective compound 
(NSC57969), which preferentially kills Pgp-expressing cells 
(Füredi et al. 2017) (Fig. 1b). The PrestoBlue-based cyto-
toxicity assay and the fluorescence-based assays measured 
in monoculture and in triple-co-culture provided concordant 
results, confirming that the triple-fluorescence assay is suit-
able for the identification of ABC transporter substrates and 
MDR-selective compounds (Table S1). Interestingly, despite 
the overlapping substrate specificity of ABCB1 and ABCG2, 
ABCG2 did not sensitize cells to NSC57969.
The triple‑fluorescence‑based cytotoxicity assay 
identifies ABC transporter substrates in the DTP 
oncology set IV
Next, we used the established co-culture model system to 
characterize the ability of the MDR ABC proteins to mod-
ulate the cytotoxic activity of 101 clinically used chemo-
therapeutics compiled in the Developmental Therapeutics 
Program’s (DTP) oncology set IV. In the primary assays 
the compounds were tested in six concentrations, using a 
robotic pipetting workstation. As expected, the majority of 
the compounds were highly toxic. As compared to the paren-
tal Mes-Sa cells, approximately 20% of the oncology set 
compounds showed reduced toxicity against its multidrug 
resistant derivatives; compounds showing reduced toxicity 
to Mes-Sa/Dx5 cells were also less toxic to Mes-Sa/B1 cells, 
proving that these compounds are P-glycoprotein substrates 
(Fig. 2a, Table S3). Interestingly, several compounds includ-
ing NSC-125066 (Bleomycin), NSC-9706 (Triethylenemela-
mine), NSC-6396 (Thioplex), and NSC-762 (Mechlore-
thamine) seemed to be more toxic against Mes-Sa/Dx5 cells. 
However, none of these compounds proved to preferentially 
kill Mes-Sa-B1 cells, indicating that the paradoxical sensi-
tivity of Mes-Sa/Dx5 cells is independent of Pgp (Table S2). 
To substantiate these results, we repeated the screen using 
the co-culture of A431 cells. Putative Pgp substrates identi-
fied by the screen performed by the Mes-Sa cells showed 
reduced toxicity to A431-B1 mCh cells (Table S3), but the 
collateral sensitivity of Mes-Sa/Dx5 cells could not be repro-
duced (Fig. S3). Next, we analyzed the differential sensitiv-
ity of parental and ABCG2-expressing A431 cells. Similarly 
to Pgp, ABCG2 conferred resistance to several compounds, 
which included known ABCG2-substrates: mercaptopurine 
(Wolf et al. 2008), irinotecan, topotecan (Maliepaard et al. 
2001), dasatinib, gefitinib, lapatinib (Ozvegy-Laczka et al. 
2004; Hegedus et al. 2009), clofarabine (Nagai et al. 2011) 
(Fig. 2b). On the other hand, none of the compounds were 
found to be more toxic to ABCG2-expressing cells.
The fluorescence‑based cytotoxicity assay identifies 
putative OATP2B1 transporter substrates
Our experiments performed with the co-culture systems 
indicated that the fluorescent protein based screen can iden-
tify ABCB1 and ABCG2 substrates. Recent evidence sug-
gests that uptake transporters can play a significant role in 
the uptake of cytotoxic drugs. However, compared to MDR 
transporters, there are no systematic studies addressing the 
contribution of uptake transporters to cytotoxicity. Recently, 
we have established a panel of cell lines expressing the 
members of the OATP transporter family, OATP1B1, 1B3 
and 2B1, and shown that A431 cells can be used to study 
the function of these OATP transporters (Patik et al. 2018). 
To address the ability of OATP2B1 to modulate the toxicity 
of the DTP compound set, we labeled OATP2B1 express-
ing A431 cells with mCherry. Transporter activity and the 
fluorescence of the cell lines were verified by FACS analysis 
(Figs. 3a, S1). Growth curves of the co-cultures confirmed 
that the relative number of the parental and OATP2B1-
expressing cells can be reliably estimated (Fig. 3b), sug-
gesting that the fluorescence-based co-culture system can be 
used to characterize the sensitivity of OATP2B1 expressing 
cells.
In the case of OATP2B1, which mediates the uptake of 
large, organic molecules, including chemotherapeutic com-
pounds (Thakkar et al. 2015), we expected an increased 
toxicity of transporter substrate chemotherapeutics, due to 
their elevated accumulation in the cells. Whereas the major-
ity of the compounds were equally toxic to A431eGFP and 
A431-2B1 cells, 13 approved chemotherapeutics showed 
increased activity against A431 cells expressing the uptake 
transporter (Fig. 4). Two compounds that showed unchar-
acteristic dose–response patterns were not pursued further 
(NSC-63878, NSC-613327), one compound (NSC-9706) 
was unavailable, and another compound was removed due 
to intrinsic fluorescence (NSC-757441). Increased toxicity 
of the remaining compounds against OATP2B1 expressing 
cells was confirmed in additional cytotoxicity experiments 
Fig. 1  Cell growth can be reliably monitored based on the fluores-
cence of differently tagged cell lines. a Cells were plated in a 384 
well plate at a final cell density of 1875 cells per well in the triple 
co-culture system (625 cells from Mes-Sa mCh/Mes-Sa Dx5 eGFP/ 
Mes-Sa-B1 mOr cell lines; 625 cells from A431 eGFP/A431-B1 
mCh/A431-G2 mOr cell lines) and at 2500 cells per well in mono-
cultures. Fluorescence corresponding to the density of the individual 
cell lines was recorded at regular intervals using a plate reader. b 
Validation of the triple-co-cultured fluorescence-based cytotoxicity 
assay.  IC50 values measured in triple coculture condition and in mon-
ocultures. Mes-Sa, Mes-Sa-B1, Mes-Sa/Dx5 and A431, A431-B1, 
A431-G2 cells were seeded in 384 well plates and were incubated in 
the presence of increasing concentrations of etoposide or the MDR-
selective compound NSC57969 in monoculture (left) and triple co-
culture conditions (middle) measured with fluorescence-based cyto-
toxic assay, and with the PrestoBlue-based cytotoxicity assay (right). 
The fluorescence-based assay measured in triple coculture condition 
and in monoculture, compared with PrestoBlue-based cytotoxic assay 
provided concordant  IC50 results (see Table S1)
◂
958 Archives of Toxicology (2019) 93:953–964
1 3
959Archives of Toxicology (2019) 93:953–964 
1 3
(Table S4), indicating that these compounds may be trans-
ported by OATP2B1 into the cells. To test this proposition, 
we evaluated the effect of these compounds on the accumu-
lation of CascadeBlue in A431-2B1 cells. The results clearly 
indicated that the putative OATP2B1-substrates identified by 
the fluorescence-based cytotoxicity screen show high affinity 
interaction with OATP2B1 (Table 1).
Discussion
Drug transporters are widely acknowledged as important 
determinants of drug pharmacokinetics, pharmacodynam-
ics, and toxicity, underlying drug–drug interactions, lack of 
therapeutic efficacy or unwanted toxicity. A large variety of 
in vitro assays have been used to characterize the interaction 
of compounds with transporters (Polli et al. 2001; Sarkadi 
et al. 2006). While each approach has unique strengths, 
there are also limitations, and classification of compounds 
as transporter substrates or inhibitors often depends on the 
specific assay.
Whereas pharmacological models based on, e.g., MDCK 
or CaCo-2 cells address the role of transporters in pharma-
cological barriers such as the gut or the blood–brain bar-
rier, here we wanted to evaluate the influence of the trans-
porters on the chemosensitivity of cancer. In this study, we 
characterize Mes-Sa (human sarcoma) and A431 (human 
epidermoid carcinoma) cells, along with their transporter-
expressing derivatives. In prior work our group has shown 
that both cell lines are suitable for the identification of 
cytotoxic MDR-substrates and MDR-selective compounds 
(Elkind et al. 2005; Hegedűs et al. 2009; Türk et al. 2009; 
Nerada et al. 2016; Füredi et al. 2017; Szabó et al. 2018; 
Temesszentandrási-Ambrus et al. 2018). To evaluate the 
influence of OATP2B1 in the context of the MDR export-
ers, we wanted to use the same in vitro model. We found 
that A431 cells are particularly well suited for the evaluation 
of OATP function. First, A431 cells show optimal growth 
and adherence characteristics favoring HTS applications. 
Second, A431 cells allow the stable expression of OATP 
transporters at relevant levels. Third, the signal to noise ratio 
measured in the A431 cell system was particularly high, 
given the very low permeability of these cells to the fluores-
cent dyes used to probe OATP function (Patik et al. 2018).
In oncological developments, in vitro cytotoxicity testing 
provides a convenient means to characterize the toxicity of 
new chemical entities. Since cellular accumulation of most 
drugs is significantly influenced by the net function of efflux 
and influx transporters, cytotoxicity of the compounds also 
depends on their interaction with transporters. Thus, cyto-
toxicity assays performed with pairs of parental and trans-
porter-expressing cells can be used to identify transporter 
substrates. In the case of efflux pumps, compounds that 
are recognized for transport are expected to show reduced 
toxicity. In contrast, uptake transporters may increase the 
toxicity of their cytotoxic substrates by enhancing their cel-
lular accumulation. The toxicity of many chemotherapeu-
tics, including new-generation anticancer agents, are known 
to be blunted by efflux transporters, but the influence of 
uptake transporters is relatively unexplored. To improve the 
throughput of transporter-based cytotoxicity screens, Bri-
macombe et al. introduced a dual-fluorescence system in 
which they compared the sensitivity of the OVCAR-8 cell 
line with that of its drug-selected derivative NCI/ADR-RES 
(expressing ABCB1/Pgp), allowing sensitive and resistant 
cells to be treated with compounds under shared conditions 
in the same wells (Brimacombe et al. 2009). Here we take 
this approach a step further to include up to three cell lines 
expressing two major efflux pumps and a ubiquitous uptake 
transporter.
The fluorescence-based viability assay is based on the 
co-culture of differentially tagged cell lines. To achieve sta-
ble expression of transporters, ABCB1 and ABCG2 were 
expressed in A431 and Mes-Sa cells by lentiviral transduc-
tion, while SLCO2B1 expressing cells were established by 
the Sleeping Beauty transposon-based gene delivery sys-
tem, using the 100× hyperactive SB transposase. In a second 
round of transduction, the cell lines were transduced with 
the fluorescent protein expressing lentiviral supernatants 
encoding mCherry, mOrange or eGFP, carefully chosen to 
allow parallel detection of the cell lines in the same well. 
Using a robotic work-flow, we were able to increase the 
throughput of our assay to include DTP’s approved oncol-
ogy set, containing most current FDA-approved anticancer 
drugs (Table S5). We developed three parallel cellular mod-
els to evaluate the ability of the triple-fluorescence assay 
to capture known ABCB1/Pgp substrates. We compared 
the sensitivity of the parental Mes-Sa cells with that of its 
drug-selected derivative (Mes-Sa/Dx5), and Mes-Sa-B1 
cells, which were engineered to overexpress Pgp. In addi-
tion, we characterized the sensitivity of parental A431 
cells in comparison to A431 cells expressing ABCB1 or 
Fig. 2  Screening results of the DTP oncology set IV measured 
against a parental Mes-Sa mCh and Pgp-expressing MDR derivatives 
[Mes-Sa/Dx5 eGFP (gray dots) or Mes-Sa-B1 mOr (black dots)]; b 
parental A431 and its ABCG2-expressing derivative (A431-G2). 
Data points represent average  pIC50 values derived from at least 
two independent experiments. To evaluate the selective toxicity of 
the compounds, resistance ratio (RR) was calculated by dividing the 
 IC50 values measured against the multidrug resistant, transporter-
expressing derivative by the cytotoxicity measured in the parental cell 
line, while the selectivity ratio (SR) was calculated as the inverse of 
RR. Compounds displaying at least a threefold difference in toxicity 
(dashed line) between the control and transporter-expressing cells 
were considered as putative ABCB1 or ABCG2 substrates (RR > 3, 
see inset); or putative MDR-selective compounds (SR > 3, see 
Table S2)
◂
960 Archives of Toxicology (2019) 93:953–964
1 3
ABCG2. Results obtained with ABCB1-overexpressing 
cells confirmed that the triple co-culture cytotoxicity assay 
identifies P-glycoprotein substrates. Overall, the three P-gp 
positive cell lines gave similar results—however, resistance 
mediated by ABCB1 was not identical in the three cell lines 
(Table S3). The Oncology Set has also been measured across 
the NCI60 cell panel, and it has been shown that the toxicity 
pattern of ABCB1/Pgp substrates is negatively correlated 
with the pattern of ABCB1 expression across the NCI60 cell 
panel (Alvarez et al. 1995; Szakács et al. 2004). As shown in 
Fig. S4a, all compounds identified as putative Pgp substrates 
by the Mes-Sa triple co-culture assay are characterized by 
a negative Pearson correlation coefficient (PCC < − 0.4), 
indicating that the fluorescence-based triple co-culture 
cytotoxicity assay can be cross-validated by data from the 
NCI-60 screen (similar results were obtained by the A431 
panel) (Fig. S4c). At the same time the in silico prediction 
missed several known Pgp substrates including vincristine, 
dasatinib, docetaxel, ixabepilone, cabazitaxel, teniposide 
and etoposide, which were identified by both the Mes-Sa 
and A431 co-culture assays (Table S4). Dasatinib, which 
was reported to be a substrate of both P-gp and ABCG2, 
was less toxic to all MDR cells. Conversely, crizotinib and 
bortezomib, both described as Pgp substrates, was only iden-
tified by the Mes-Sa panel (RR = 9.9 and 4.3 for Mes-Sa-
B1 and RR = 21.3 and 17 for Mes-Sa/Dx5, respectively), 
while the resistance ratio of these compounds were below 
the established threshold in the A431 cells (RR = 2.6 and 
2.7, respectively). Interestingly, the DTP database contains 
toxicity patterns that are positively correlated to the expres-
sion of ABCB1 across the NCI60 cell panel, indicating that 
Pgp may potentiate, rather than reduce the toxicity of certain 
Fig. 3  Characterization of the fluorescence-based OATP2B1 uptake 
transporter-expressing A431 co-culture system. a Transport activity 
of OATP2B1 can be selectively measured in the co-cultured cells. 
Co-culture of parental A431 eGFP (grey) and transporter express-
ing A431-2B1 mCh (black) cells were stained by Cascade Blue in 
the absence (middle) or presence (right) of the OATP2B1 inhibitor 
estrone-3-sulfate (cells without Cascade Blue are shown in the left 
panel). CB is selectively taken up by OATP2B1-expressing cells. 
b Growth of A431 eGFP and A431-2B1 mCh cells can be reli-
ably monitored based on the differential tagging of cells. Cells were 
seeded in 384-well plates in monoculture (2500 cells/well) and in co-
culture conditions (1250 A431 eGFP + 1250 A431-2B1 cells/well). 
The cells were incubated for 144 h in a final volume of 60 µl, at 37 °C 
and 5%  CO2, under humidified atmosphere. Cell growth correspond-
ing to each cell line was recorded using a microplate reader
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compounds (Szakács et al. 2004). Indeed, compounds such 
as NSC57969 show preferential toxicity to Pgp-expressing 
cells, proving that this well-studied drug resistance mecha-
nism may be exploited to target resistant cancer (Hall et al. 
2009). However, as seen in Figs. 2a and S3, the paradoxical 
toxicity of the compounds is restricted to Mes-Sa/Dx5 cells, 
indicating that their increased toxicity is unrelated to Pgp 
(Szakács et al. 2014).
Increasing evidence indicates that OATPs show altered, 
usually increased expression in various types of cancer, 
e.g., in breast, colon, lung and prostate cancers (Obaidat 
et al. 2012; Thakkar et al. 2015; Kovacsics et al. 2017). 
Increased OATP2B1 expression has been demonstrated in 
a colon cancer cell line (Tamai et al. 2000), in bone cysts 
(Liedauer et al. 2009) and in glioma (Bronger et al. 2005). 
OATP overexpression may be beneficial for tumor cells by 
increased nutrient or hormone uptake. Indeed, it has been 
shown that increased uptake of hormones (ES, DHEAS) by 
OATPs 1A2, 1B3 and 2B1 resulted in increased survival of 
breast cancer cells (Nozawa et al. 2004; Arakawa et al. 2012; 
Fig. 4  Screening results of the DTP Oncology Set IV measured 
against parental A431 and its OATP2B1-expressing derivative 
(A431-2B1). Compounds displaying at least a threefold difference in 
toxicity (dashed line) between the control and transporter-expressing 
cells were considered as putative substrates (SR > 3, see inset)
Table 1  Inhibition of OATP2B1-mediated Cascade Blue (CB) uptake 
by the putative OATP2B1 substrates identified in the cytotoxicity 
screen
Transport of CB (10 µM) was measured for 30 min in increasing con-
centrations of the investigated compounds.  IC50 values were deter-
mined by measuring the intracellular accumulation of Cascade Blue 
in the presence of increasing concentrations of OATP2B1 interacting 
compounds. Experiments were performed in triplicates with three 
parallels in each biological replicate. Average ± SD values of  IC50 
values are shown
NSC number Name IC50 (µM)
NSC-125066 Bleomycin 64.15 ± 6.1
NSC-712807 Capecitabine 124.01 ± 6.42
NSC-628503 Docetaxel 11.32 ± 0.38
NSC-616348 Irinotecan 17.03 ± 1.46
NSC-180973 Tamoxifen 10.99 ± 0.7
NSC-740 Methotrexate 265.50 ± 31.38
NSC-122819 Teniposide 4.59 ± 0.4
NSC-141540 Etoposide 1.88 ± 0.32
NSC-6396 Thioplex 574.28 ± 282.7
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Matsumoto et al. 2015). Moreover, clinical data suggests 
that testosterone uptake by OATP1B3 or DHEAS transport 
by OATP2B1 may be crucial in prostate cancer progression 
(Hamada et al. 2008; Wright et al. 2011). Therefore, inhibi-
tion of OATP function presents a possible strategy to cure 
hormone dependent cancers.
On the other hand, multispecific OATPs, such as 
OATP1A2, 1Bs and 2B1 may also influence the in vivo 
fate of drugs as well as their intratumoral concentration. 
Hence, increased cellular uptake of anticancer compounds 
by these OATPs may lead to increased drug sensitivity, 
offering a strategy to increase the efficacy of chemother-
apy. To date, only few studies have investigated the role of 
OATPs in drug sensitivity. OATP1B1 has been shown to 
sensitize cells toward flavopiridol (Brenner et al. 2015), 
and OATP1B3 and OATP2B1 were shown to increase the 
toxicity of methotrexate and atorvastatin, respectively (Abe 
et al. 2001). On the analogy of efflux transporters, corre-
lations were found between drug activity and the mRNA 
expression of SLC transporters across the NCI60 cell panel 
(Okabe et al. 2008; Lancaster et al. 2013). However, besides 
the above mentioned in silico screen, a systemic search for 
OATP-mediated cytotoxicity has not been undertaken. 
After validating the fluorescence-based co-culture system 
with traditional cytotoxicity experiments performed in 
monocultures (Fig. 1, Table S1), and the identification of 
known ABCB1 and ABCG2 substrates (Fig. 2, Table S3) 
we repeated the screen subjecting the co-cultures of parental 
and OATP2B1-expressing cells to the drug panel. In agree-
ment with the directionality of the transport, the assay has 
failed to identify compounds showing reduced toxicity in 
transporter-expressing cells. Conversely, 13 chemotherapeu-
tics proved to be more toxic against OATP2B1 overexpress-
ing A431 cells, as compared to the parental line. Except 
for methotrexate and etoposide, none of these compounds 
have been reported to interact with OATP2B1. Etoposide 
was previously reported as substrate of OATP2B1 (Fahr-
mayr et al. 2012), and its close structural analog teniposide 
was reported to be an inhibitor for both hepatic transport-
ers OATP1B1 and OATP1B3 (De Bruyn et al. 2013). The 
uniform platform introduced here allows the comparative 
analysis of transporter-effect on cell survival. It is interest-
ing to note that both etoposide and teniposide are also rec-
ognized by ABCG2 (Allen et al. 2003), and etoposide is 
additionally recognized by ABCB1, which may mask the 
OATP2B1-mediated effect in tumor cells expressing several 
transporters. Docetaxel is also transported by all the three 
studied transporters, and further studies suggest interac-
tion with OATP1B3 (Baker et al. 2009). However, it was 
reported that taxol is not transported by OATP2B1 (Leb-
lanc et al. 2018), which was confirmed by our screening 
results (Fig. 4). We find that tamoxifen, which was reported 
to be a substrate of OATP1B1 (Gao et al. 2017), shows high 
affinity interaction with OATP2B1 (Table S5). This drug is 
of special interest since it is commonly used for the treat-
ment of ER-positive breast cancer and the facilitated uptake 
of tamoxifen into cancer cells by uptake transporters can, 
therefore, possess an advantage. However, since also efflux 
transporters (ABCB1 and ABCG2) recognize tamoxifen, the 
net-effect of this uptake/efflux interplay is unknown, when 
both types of transporters are expressed. The clinical rele-
vance of transporter-mediated drug uptake depends on many 
pathophysiological factors including expression levels or the 
context of efflux transporters. The results presented in this 
study prove that in vitro, OATP2B1 can sensitize cells to its 
transported substrates. Further research should evaluate the 
role of the interplay of transporters in drug resistant cancer, 
and it will be essential to fully understand the full plethora 
of transporters involved in drug disposition. The methodol-
ogy presented here provides an experimental tool for the 
comparison of efflux and uptake transport mechanisms in 
different variants of the same cell line.
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